Compare Abeona Therapeutics Inc (ABEO) vs Franklin Resources, Inc. (BEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Franklin Resources, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Franklin Resources, Inc. trades at $33.51 (market cap $17.85B). The key difference: Franklin Resources, Inc. is far larger — about 47.8× Abeona Therapeutics Inc's market cap, and Franklin Resources, Inc. pays a 3.84% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BEN | |
|---|---|---|
Market Cap | $373.32M | $17.85B |
Sector | Health | Financials |
52-Week High | $7.23 | $34.44 |
52-Week Low | $4.17 | $21.18 |
Enterprise Value | $228.22M | $29.68B |
Dividend Yield | — | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Franklin Resources (BEN) trades at $34.36, up 0.73% on the day, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats, with Q2 2026 results expected on July 31, 2026. Revenue grew to $8.77 billion in 2025, and AUM increased to $1.79 trillion in June 2026, driven by net inflows and strategic expansions into alternatives and digital assets.
Outlook remains positive with earnings momentum and dividend yield near 4%, but risks include volatile cash flows and high P/E ratio. Analyst consensus is mixed with a $33 price target slightly below current levels, suggesting cautious optimism amid solid fundamentals and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →
